These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33040622)

  • 1. Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia - a study of the Acute Leukemia Working Party of the EBMT.
    Heinicke T; Labopin M; Polge E; Stelljes M; Ganser A; Tischer J; Brecht A; Kröger N; Beelen DW; Scheid C; Bethge W; Dreger P; Bunjes D; Wagner E; Platzbecker U; Savani BN; Nagler A; Mohty M
    Leuk Lymphoma; 2021 Feb; 62(2):399-409. PubMed ID: 33040622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Rodríguez-Arbolí E; Labopin M; Tischer J; Brecht A; Ganser A; Finke J; Blau IW; Kröger N; Kalhs P; Forcade E; Bunjes D; Spyridonidis A; Savani B; Nagler A; Mohty M
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):2165-2173. PubMed ID: 32717436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis.
    Sheth V; Labopin M; Canaani J; Volin L; Brecht A; Ganser A; Mayer J; Labussière-Wallet H; Bittenbring J; Shouval R; Savani B; Mohty M; Nagler A
    Bone Marrow Transplant; 2019 Apr; 54(4):531-539. PubMed ID: 30087463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
    Saraceni F; Labopin M; Brecht A; Kröger N; Eder M; Tischer J; Labussière-Wallet H; Einsele H; Beelen D; Bunjes D; Niederwieser D; Bochtler T; Savani BN; Mohty M; Nagler A
    J Hematol Oncol; 2019 Apr; 12(1):44. PubMed ID: 31023346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis.
    Braitsch K; Schwarz A; Koch K; Hubbuch M; Menzel H; Keller U; Götze KS; Bassermann F; Herhaus P; Verbeek M
    Ann Hematol; 2022 Jun; 101(6):1311-1319. PubMed ID: 35364726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential Conditioning With FLAMSA Does Not Improve Outcomes of Allogeneic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia Patients.
    Massoud R; Klyuchnikov E; Steiner N; Zeck G; Heidenreich S; Langebrake C; Niederwieser C; Rathje K; Gagelmann N; Janson D; Wolschke C; Ayuk F; Kröger N
    Transplant Cell Ther; 2024 Oct; ():. PubMed ID: 39419178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis.
    Rodríguez-Arbolí E; Labopin M; Eder M; Brecht A; Blau IW; Huynh A; Forcade E; Tischer J; Bethge W; Bondarenko S; Verbeek M; Bulabois CE; Einsele H; Stölzel F; Savani B; Spyridonidis A; Bazarbachi A; Giebel S; Brissot E; Schmid C; Nagler A; Mohty M
    Bone Marrow Transplant; 2022 Jun; 57(6):934-941. PubMed ID: 35393528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
    Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
    J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT.
    Giebel S; Labopin M; Sobczyk-Kruszelnicka M; Stelljes M; Byrne JL; Fegueux N; Beelen DW; Rovira M; Spyridonidis A; Blaise D; Bornhäuser M; Karadogan I; Savani BN; Nagler A; Mohty M;
    Bone Marrow Transplant; 2021 Feb; 56(2):481-491. PubMed ID: 32892216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT.
    Heinicke T; Labopin M; Polge E; Niederwieser D; Platzbecker U; Sengelov H; Choi G; Cornelissen J; Blaise D; Kuball J; van Gorkom G; Schaap N; Potter V; Paul F; Savani BN; Nagler A; Mohty M
    Bone Marrow Transplant; 2020 Apr; 55(4):729-739. PubMed ID: 31645668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
    Dhere V; Edelman S; Waller EK; Langston A; Graiser M; Connolly EC; Switchenko JM; Esiashvili N; Khan MK
    Leuk Lymphoma; 2018 Apr; 59(4):837-843. PubMed ID: 28782395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity.
    Eapen M; Brazauskas R; Hemmer M; Perez WS; Steinert P; Horowitz MM; Deeg HJ
    Blood Adv; 2018 Aug; 2(16):2095-2103. PubMed ID: 30135184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Malard F; Labopin M; Stuhler G; Bittenbring J; Ganser A; Tischer J; Michallet M; Kröger N; Schmid C; Huynh A; Hallek M; Savani BN; Mohty M; Nagler A
    Biol Blood Marrow Transplant; 2017 Feb; 23(2):278-284. PubMed ID: 27816650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
    Patel SS; Rybicki L; Pohlman B; Bolwell B; Gerds AT; Hamilton BK; Hanna R; Kalaycio M; Majhail NS; Sobecks R
    Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):160-165. PubMed ID: 31628924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation.
    Lucchini G; Labopin M; Beohou E; Dalissier A; Dalle JH; Cornish J; Zecca M; Samarasinghe S; Gibson B; Locatelli F; Bertrand Y; Abdel-Rahman F; Socie G; Sundin M; Lankester A; Sedlacek P; Hamladji RM; Heilmann C; Afanasyev B; Hough R; Peters C; Bader P; Veys P
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):467-474. PubMed ID: 27916512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
    Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
    Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
    Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
    [No Abstract]   [Full Text] [Related]  

  • 18. Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party.
    Bazarbachi AH; Al Hamed R; Labopin M; Afanasyev B; Hamladji RM; Beelen D; Eder M; Scheid C; Wu D; Bunjes D; Stepensky P; Tischer J; Kröger N; Peric Z; Aljurf M; Giebel S; Nagler A; Mohty M
    Bone Marrow Transplant; 2020 Mar; 55(3):595-602. PubMed ID: 31562398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML.
    Holtick U; Herling M; Pflug N; Chakupurakal G; Leitzke S; Wolf D; Hallek M; Scheid C; Chemnitz JM
    Ann Hematol; 2017 Mar; 96(3):479-487. PubMed ID: 27909887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Heinicke T; Labopin M; Schmid C; Polge E; Socié G; Blaise D; Mufti GJ; Huynh A; Brecht A; Ledoux MP; Cahn JY; Milpied N; Scheid C; Hicheri Y; Mohty M; Savani BN; Nagler A
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2224-2232. PubMed ID: 30009981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.